AIMP1 and neoplasm: Low-dose EMAP II has been confirmed to increase the blood-tumor barrier (BTB) permeability by opening tight junction (TJ) via Rho A, PKC or other signal pathways (Li et al., 2012, 2015; Xie et al., 2012).